After a brief review of the history of the development of technetium-99m-labeled
radiopharmaceuticals, the use of technetium chelates in high-capacity systems is discussed …

Highlights•Technetium-99m (Tc-99m) has long been a mainstay in clinical nuclear
medicine.•Tc-99m radioligands that target low-density, specific proteins have been …

METhODS Patient Population and Study Protocol The study group was recruited from
patients referred to our Nuclear Medicine laboratory for 201'flexercise myocardial scm …

Background 99m Tc-labeled teboroxime shows high myocardial extraction in both in vivo
animal and in vitro cell culture and isolated heart studies. Whereas in vivo studies show …

Since its approval for clinical use in 1975, thallium-201 has been the mainstay for
myocardial perfusion imaging to diagnose and manage patients with coronary artery …

Teboroxime, a new technetium-99m-labeled myocardial perfusion tracer, possesses rapid
myocardial kinetics. Whereas this agent is routinely imaged after separate stress and rest …

This study examined the imaging results and kinetics of technetium 99m teboroxime after its
intracoronary injection during papaverine-induced coronary hyperemia in patients with one …

This is the first article in a four-part series on new radiopharmaceuticals. Upon completion of
this article, the nuclear medicine technologist will be able to (1) give an overview of the new …

accepted Oct. 5, 1994. For correspondence or reprints contact: Henry Gewirtz, MD,
Massachusetts General Hospital, Vin cent Bumham 3, Nuclear Cardiology, 32 Fruit St …

One of the strongest points of the field of nuclear medicine has been its ability to adapt to the
development of new drugs, new machines, and changing clinical needs. As in many other …